Sevident, INC.:1242717 [16-064431] sbir phase i topic

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201600053C
Awardee
Awarding agency
Obligated
$299,338

Award facts

Opportunity
  • N01CO69001 Solicitation number
Contract value 100% obligated
$299,338.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Hayward, CA 94545, USA

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase I contract to Sevident, Inc., a woman-owned small business, for the amount of $299,338. The contract has a firm-fixed price and is set aside for small businesses. The contract is for the SEVIDENT, INC.:1242717 [16-064431] SBIR PHASE I TOPIC, with a performance period ending on June 18, 2017. The contract was awarded on September 19, 2016.

Quick answers

Who was awarded contract HHSN261201600053C?

HHSN261201600053C was awarded to Sevident, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600053C worth?

The government has obligated $299,338 on HHSN261201600053C.

Was contract HHSN261201600053C competed?

The extent of competition for HHSN261201600053C was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award